World's Best Scientists 2026 revealed!

Overview

Li Zhang is a researcher affiliated with Sun Yat-sen University in China, whose work is primarily situated in the field of medicine with a focus on oncology and pulmonary and respiratory medicine. Their research output includes substantial contributions to cancer research, molecular biology, and surgery.

Their research topics cover a variety of areas related to cancer and respiratory diseases, including:

  • Lung Cancer Treatments and Mutations
  • Lung Cancer Research Studies
  • Lung Cancer Diagnosis and Treatment
  • Cancer Genomics and Diagnostics
  • Cancer Immunotherapy and Biomarkers
  • Colorectal Cancer Treatments and Studies
  • Head and Neck Cancer Studies

Frequent publication venues for Li Zhang include:

  • Journal of Clinical Oncology
  • Annals of Oncology
  • Journal of Thoracic Oncology
  • Lung Cancer
  • Thoracic Cancer

Li Zhang has collaborated extensively with several researchers, including:

  • Wenfeng Fang
  • Yan Huang
  • Yunpeng Yang
  • Hongyun Zhao
  • Yuanyuan Zhao

Recent significant papers authored or coauthored by Li Zhang include:

  • Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial, 2021, The Lancet Oncology
  • Apatinib Plus Gefitinib as First-Line Treatment in Advanced EGFR-Mutant NSCLC: The Phase III ACTIVE Study (CTONG1706), 2021, Journal of Thoracic Oncology
  • Ivonescimab Plus Chemotherapy in Non-Small Cell Lung Cancer With EGFR Variant, 2024, JAMA
  • Gemcitabine Plus Cisplatin Versus Fluorouracil Plus Cisplatin as First-Line Therapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: Final Overall Survival Analysis of GEM20110714 Phase III Study, 2021, Journal of Clinical Oncology
  • Efficacy, safety, and biomarker analysis of Camrelizumab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma (CAPTAIN study), 2021, Journal for ImmunoTherapy of Cancer

Li Zhang's work demonstrates a consistent focus on treatments and clinical trials for various types of cancer, particularly lung cancer and nasopharyngeal carcinoma, integrating chemotherapy, immunotherapy, targeted therapies, and biomarker analysis.

Best Publications

  • Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China

    Chaomin Wu;Xiaoyan Chen;Yanping Cai;Jia’an Xia

  • Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

    Caicun Zhou;Yi Long Wu;Gongyan Chen;Jifeng Feng

  • Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial

    Keunchil Park;Eng Huat Tan;Ken O'Byrne;Li Zhang

  • Selective chemical labeling reveals the genome-wide distribution of 5-hydroxymethylcytosine

    Chun Xiao Song;Keith E. Szulwach;Ye Fu;Qing Dai

  • Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis

    Pierre Blanchard;Pierre Blanchard;Anne Lee;Sophie Marguet;Julie Leclercq

  • Systematic comparison of constitutive promoters and the doxycycline-inducible promoter.

    Jane Yuxia Qin;Jane Yuxia Qin;Li Zhang;Kayla L. Clift;Imge Hulur

  • Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation

    Nan Chen;Wenfeng Fang;Jianhua Zhan;Shaodong Hong

  • Development and Validation of a Nomogram for Predicting Survival in Patients With Resected Non–Small-Cell Lung Cancer

    Wenhua Liang;Li Zhang;Gening Jiang;Qun Wang

  • Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial

    Yuankai Shi;Li Zhang;Xiaoqing Liu;Caicun Zhou

  • Sperm, but Not Oocyte, DNA Methylome Is Inherited by Zebrafish Early Embryos

    Lan Jiang;Jing Zhang;Jing-Jing Wang;Jing-Jing Wang;Lu Wang;Lu Wang

  • Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial.

    Roy S Herbst;Yan Sun;Wilfried E E Eberhardt;Paul Germonpré

  • Risk of COVID-19 for patients with cancer.

    Hanping Wang;Li Zhang

  • Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study.

    Jing Huang;Jianming Xu;Yun Chen;Wu Zhuang

  • Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial

    Li Zhang;Yan Huang;Shaodong Hong;Yunpeng Yang

  • Nestin is required for the proper self-renewal of neural stem cells.

    Donghyun Park;Donghyun Park;Andy Peng Xiang;Frank Fuxiang Mao;Frank Fuxiang Mao;Li Zhang

  • Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non–Small Cell Lung Cancer in the Global Phase III ALEX Study

    D. Ross Camidge;Rafal Dziadziuszko;Solange Peters;Tony Mok

  • Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial

    Yi Long Wu;Jin Soo Lee;Sumitra Thongprasert;Chong Jen Yu

  • Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials

    Wenfeng Fang;Yunpeng Yang;Yuxiang Ma;Shaodong Hong

  • Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non–Small-Cell Lung Cancer

    Ramaswamy Govindan;Aleksandra Szczesna;Myung Ju Ahn;Claus Peter Schneider

  • EBV-driven LMP1 and IFN-γ up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy

    Wenfeng Fang;Jianwei Zhang;Shaodong Hong;Jianhua Zhan

Frequent Co-Authors

Yi-Long Wu
Yi-Long Wu Guangdong Provincial People’s Hospital
Caicun Zhou
Caicun Zhou Tongji University
Bruce T. Lahn
Bruce T. Lahn University of Chicago
Tony Mok
Tony Mok Chinese University of Hong Kong
Gang Chen
Gang Chen Guangxi Medical University
James Chih-Hsin Yang
James Chih-Hsin Yang National Taiwan University
Jifeng Feng
Jifeng Feng Nanjing Medical University
Kenneth J. O'Byrne
Kenneth J. O'Byrne Queensland University of Technology
Luis Paz-Ares
Luis Paz-Ares Complutense University of Madrid
Michael Boyer
Michael Boyer University of Utah

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Are you exploring alternative career routes or flexible study options related to Medicine in the USA? Online education now offers many accredited pathways for both newcomers and experienced professionals in healthcare and related fields.

For registered nurses looking to advance their careers, consider targeted bridge programs like rn to fnp programs or rn to bsn online with no clinicals. These degrees provide a fast track to higher qualifications, often with flexible schedules and minimal on-site requirements.

If you’re interested in the science behind health and wellness, the best online food science degree programs can open doors to careers in nutrition, research, or food safety. Aspiring health administrators can pursue leadership by enrolling in whats the best online mha program for working adults, which is ideal for those balancing professional commitments.

With flexible online options, you can customize your learning journey, access diverse healthcare fields, and build a fulfilling career that makes a difference.

Best Scientists Citing Li Zhang

Trending Scientists

Recently Published Articles